Evidence
Bioorg Chem. 2024 Jan 4;143:107071. doi: 10.1016/j.bioorg.2023.107071. Online ahead of print.
ABSTRACT
Farnesoid X receptor (FXR) was considered as a promising drug target in the treatment of cholestasis, drug-induced liver injury, and non-alcoholic steatohepatitis (NASH). However, the existing FXR agonists have shown different degrees of side effects in clinical trials without clear interpretation. MET-409 in clinical phase Ⅲ, has been proven significantly fewer side effects than that of other FXR agonists. This may be due to the completely different structure of FEX and other non-steroidal FXR agonists. Herein, the structure-based drug design was carried out based on FEX, and the more active FXR agonist LH10 (FEX EC50 = 0,3 μM; LH10 EC50 = 0.14 μM)) was screened out by the comprehensive SAR studies. Furthermore, LH10 exhibited robust hepatoprotective activity on the ANIT-induced cholestatic model and APAP-induced acute liver injury model, which was even better than positive control OCA. In the nonalcoholic steatohepatitis (NASH) model, LH10 significantly improved the pathological characteristics of NASH by regulating several major pathways including lipid metabolism, inflammation, oxidative stress, and fibrosis. With the above attractive results, LH10 is worthy of further evaluation as a novel agent for the treatment of liver disorders.
PMID:38199141 | DOI:10.1016/j.bioorg.2023.107071
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
🌐 90 Days
VR Related Evidence Matrix
- Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice
- Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
- Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
- Identification of 1,3,8-triazaspiro[4.5]decane-2,4-dione Derivatives as a Novel Delta Opioid Receptor-Selective Agonist Chemotype
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Discovery of a quinoline-containing compound JT21-25 as a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1)
- Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway
- NCP, a dual kappa and mu opioid receptor agonist, is a potent analgesic against inflammatory pain without reinforcing or aversive properties
- Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease
- Effects of selenium nanoparticles produced by Lactobacillus acidophilus HN23 on lipid deposition in WRL68 cells
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- NAFLD and NASH: etiology, targets and emerging therapies
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures
- Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A2AR improves hepatic and cardiac dysfunction of NASH mice
- Peptide-derived ligands for the discovery of safer opioid analgesics
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Orphan GPR52 as an emerging neurotherapeutic target
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
- What is the best first choice oral drug therapy for OAB?
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study
- Fluoride transport in Arabidopsis thaliana plants is impaired in Fluoride EXporter (FEX) mutants
- Tackling myelin deficits in neurodevelopmental disorders using drug delivery systems
- Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Larsucosterol: Endogenous Epigenetic Regulator for Treating Chronic & Acute Liver Diseases
- Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention
- MolProphet: A One-Stop, General Purpose, and AI-Based Platform for the Early Stages of Drug Discovery
- Exploring Bile-Acid Changes and Microflora Profiles in Chicken Fatty Liver Disease Model
- ENPP2/Autotaxin: The potential drug target for alcoholic liver disease identified through Mendelian randomization analysis
- Ethanol extracts of Isochrysis zhanjiangensis alleviate acute alcoholic liver injury and modulate intestinal bacteria dysbiosis in mice
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Peripheral mu-opioid receptor activation by dermorphin [D-Arg2, Lys4] (1-4) amide alleviates behavioral and neurobiological aberrations in rat model of chemotherapy-induced neuropathic pain
- Serine protease inhibitor from the muscle larval Trichinella spiralis ameliorates non-alcoholic fatty liver disease in mice via anti-inflammatory properties and gut-liver crosstalk
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Exploring the Potential Role of Massa Medicata Fermentata in Alcoholic Liver Injury Disease Based on Network Pharmacology and Animal Experiments
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Paeonol attenuates nonalcoholic steatohepatitis by regulating intestinal flora and AhR/NLRP3/Caspase-1 metabolic pathway
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- Clinicopathological features of Sjogren's syndrome complicated with liver injury
- Isolation, purification, and structural characterization of polysaccharides from Codonopsis pilosula and its therapeutic effects on non-alcoholic fatty liver disease in vitro and in vivo
- The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
- Dermorphin [D-Arg2, Lys4] (1-4) Amide Alleviates Frostbite-Induced Pain by Regulating TRP Channel-Mediated Microglial Activation and Neuroinflammation
- Sotagliflozin attenuates liver associated disorders in cystic fibrosis rabbits
- Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARalpha and suppressing HIF1
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- The effect of drug holidays on sexual dysfunction in men treated with selective serotonin reuptake inhibitors (SSRIs) other than fluoxetine: an 8-week open-label randomized clinical trial
- FDA-approved disulfiram as a novel treatment for aggressive leukemia
Evidence Blueprint
Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
🌐 365 Days
VR Related Evidence Matrix
- Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment
- Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice
- Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders
- Rational design of FXR agonists: a computational approach for NASH therapy
- Advances in traditional Chinese medicine treatment of non-alcoholic fatty liver disease via farnesoid X receptor
- Kaempferol ameliorated alcoholic liver disease through inhibiting hepatic bile acid synthesis by targeting intestinal FXR-FGF15 signaling
- Natural Products in Non-alcoholic Fatty Liver Disease (NAFLD): Novel lead discovery for drug development
- FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH
- FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease
- Protective effects of scutellaria-coptis herb couple against non-alcoholic steatohepatitis via activating NRF2 and FXR pathways in vivo and in vitro
- A turn-on fluorescent probe for detecting and bioimaging of HOCl in inflammatory and liver disease models
- Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
- Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries
- Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
- Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis
- Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR
- Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)
- Identification of 1,3,8-triazaspiro[4.5]decane-2,4-dione Derivatives as a Novel Delta Opioid Receptor-Selective Agonist Chemotype
- Effects of flaxseed powder in improving non-alcoholic fatty liver by regulating gut microbiota-bile acids metabolic pathway through FXR/TGR5 mediating
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- Identification of 3H-benzo[b] [1,4] diazepine derivatives as PPARα agonists by in silico studies and biochemical evaluation
- Kaempferol and nicotiflorin ameliorated alcohol-induced liver injury in mice by miR-138-5p/SIRT1/FXR and gut microbiota
- Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)
- Discovery of a CB2 and 5-HT1A receptor dual agonist for the treatment of depression and anxiety
- Discovery of a quinoline-containing compound JT21-25 as a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1)
- Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
- The Effects of Chronic Naltrexone on Reinstatement of Opioid-Induced Drug-Seeking Behavior and Antinociception
- Novel quinazolinone Derivatives: Design, synthesis and in vivo evaluation as potential agents targeting Alzheimer disease
- Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice
- The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
- Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway
- NCP, a dual kappa and mu opioid receptor agonist, is a potent analgesic against inflammatory pain without reinforcing or aversive properties
- Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease
- Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics
- Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
- Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
- Synthesis, computational simulations and biological evaluation of new dual 5HT1A/5HT7 receptor ligands based on purine-2,6-dione scaffold
- Effects of selenium nanoparticles produced by Lactobacillus acidophilus HN23 on lipid deposition in WRL68 cells
- Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
- Identification of drug repurposing candidates for the treatment of anxiety: A genetic approach
- Mechanism and antibacterial synergies of poly(Dabco-BBAC) nanoparticles against multi-drug resistant Pseudomonas aeruginosa isolates from human burns
- Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- The Differential Influence of PZM21, A Nonrewarding μ-opioid Receptor Agonist With G Protein Bias, on Behavioural Despair and Fear Response in Mice
- Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys
- Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
- Anxiolytics: Appropriate Use of Benzodiazepine Receptor Agonists
- A dual nociceptin and mu opioid receptor agonist exhibited robust antinociceptive effect with decreased side effects
- Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
- Hyocholic acid retards renal fibrosis by regulating lipid metabolism and inflammatory response in a sheep model
- Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model
- Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
- hERG agonists pose challenges to web-based machine learning methods for prediction of drug-hERG channel interaction
- Metformin: update on mechanisms of action on liver diseases
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- NAFLD and NASH: etiology, targets and emerging therapies
- Progress of research on the role of active ingredients of Citri Reticulatae Pericarpium in liver injury
- Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D3 (D3R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection